DOCSLIB.ORG

Wellcome Trust Annual Review 2007

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

WELLCOME TRUST ANNUAL REVIEW 1 October 2006–30 September 2007 ANNUAL REVIEW 2007 The Wellcome Trust is the largest charity in the UK. It funds innovative biomedical research, in the UK and internationally, spending over £500 million each year to support the brightest scientists with the best ideas. The Wellcome Trust supports public debate about biomedical research and its impact on health and wellbeing. www.wellcome.ac.uk THE WELLCOME TRUST The Wellcome Trust is the largest charity in the UK. It funds innovative biomedical research, in the UK and internationally, and supports public debate about biomedical research and its impact on health and wellbeing. 123 CONTENTS BOARD OF GOVERNORS 2 Director’s statement William Castell Chairman Achieving our objectives Adrian Bird 4 Advancing knowledge Deputy Chairman 16 Using knowledge Kay Davies 24 Engaging society Christopher Fairburn 30 Developing people Patricia Hodgson 36 Facilitating research Richard Hynes 40 Developing our organisation Peter Rigby The year in review Alastair Ross Goobey* 41 Corporate activities Peter Smith 42 Financial summary 2006/07 Edward Walker-Arnott 44 Funding developments 2006/07 As at January 2008 46 Streams funding 2006/07 *While finalising this publication, we were saddened to learn that Alastair Ross Goobey had died, following a 48 Technology Transfer long illness. Alastair was an outstanding Governor and extraordinary friend of the Wellcome Trust. A Governor 49 Wellcome Trust Genome Campus since 2002, his advice was instrumental in helping to develop the investments of the Trust. He took a 50 Public Engagement great interest in all aspects of our activities and will be 51 Wellcome Collection sadly missed by those who worked with him. 52 Advisory committees Images This Annual Review covers the 1 A trypanosome parasite. 3 Examining material in 5 The Beagle 2 spacecraft. Wellcome Trust’s financial year, from 2 Stephen Fry in the Wellcome Library. 6 The Africa Centre for 1 October 2006 to 30 September 2007. Wellcome Collection. 4 Malaria parasites inside Health and Population red blood cells. Studies. CONTENTS 1 45 6 EXECUTIVE BOARD MAKING A DIFFERENCE Developing people: To foster a Mark Walport The Wellcome Trust’s mission is research community and individual Director of the Wellcome Trust to foster and promote research with researchers who can contribute to the advancement and use of knowledge Ted Bianco the aim of improving human and animal Director of Technology Transfer health. During 2005–2010, Facilitating research: To promote the our aims are: best conditions for research and the John Cooper use of knowledge Director of Resources Advancing knowledge: To support research to increase understanding Developing our organisation: To use David Lynn of health and disease, and its our resources efficiently and effectively. Head of Strategic Planning and Policy societal context Clare Matterson Using knowledge: To support the Director of Medicine, development and use of knowledge Society and History to create health benefit David Phillipps Engaging society: To engage with Director of Finance society to foster an informed climate Alan Schafer within which biomedical research Head of Molecular and can flourish Physiological Sciences John Stewart Head of Legal and Company Secretary Danny Truell Chief Investment Officer As at January 2008 Strategic Plan updates, summarising progress in achieving specific objectives during 2006/07, can be found at www.wellcome.ac.uk/strategicplan. DIRECTOR’S STATEMENT 2 BEING BOLD Sometimes big is definitely better… 12 3 One of the benefits of having significant Crucially, this work has only been made The Consortium was not the only sums to award in grants is the possible by the availability of a dense notable ‘big science’ achievement of the opportunity to make major investments – map of genetic markers – an outcome of year. January 2007 saw the opening of to think big. We have been in the the Human Genome Project, the the Diamond synchrotron, a joint venture fortunate position of being able to do sequencing of which identified sites of with the UK Government (page 37). This that while maintaining our core support single-letter variation in the human initiative, the largest scientific for curiosity-driven investigator-led genetic code (so-called single nucleotide infrastructure project in the UK for 40 proposals. But rather than do ‘more of polymorphisms, SNPs). Recognising the years, has been many years in gestation the same’ we have consciously set aside value of SNPs as genetic markers, we and it gives me great pleasure to see large sums to be spent on the truly supported the SNP Consortium, a such a world-class facility up and running. innovative, large-scale projects that will public–private partnership that mapped The value of structural approaches, have enduring impact. This year we can hundreds of thousands of SNPs across where Diamond will have its biggest see how this policy has borne fruit the genome and made them freely biological impact, is amply illustrated by magnificently. available for use in research. the continuing success of the Structural The undoubted highlight has been the From the SNP Consortium emerged the Genomics Consortium (page 37). stream of papers emerging from the International HapMap Project, to which Another public–private partnership, and Wellcome Trust Case Control we have also contributed support. The based on an international collaboration Consortium (page 6). Identifying genes HapMap Project is characterising human involving the UK, Canada and Sweden, associated with common diseases has genetic variation across different human the Structural Genomics Consortium has been a goal of human geneticists for populations. It is variation between confounded sceptics – easily surpassing decades, yet with a few notable individuals that will underpin differing its targets. Protein structures, again exceptions progress has been susceptibilities to disease. freely released into the public domain, frustratingly slow. It has taken advances While SNPs still appear to be the main have given insight into fundamental in technology, methodology and source of human genetic variation, copy biological questions and are also of statistical tools to arrive at a situation number variation is also turning out to be direct practical benefit, stimulating new where reliable associations can now be significant (pages 6–7). Blocks of DNA may drug development. identified. be missing or present in different numbers Large-scale high-throughput More than 30 genes have been of copies in different people. We are now approaches are one of the strengths of pinpointed by the Consortium using this discovering that this feature is more the Wellcome Trust Sanger Institute. It approach, and others are likely to be common than we thought, is distinct continues to play a key role in unravelling confirmed by more detailed follow-up from SNP variation, and impacts on the mysteries of the human genome – an work. They are providing valuable leads health. In a new venture funded this year, entity that is more complex than anyone for researchers investigating the biology the Case Control Consortium will be had thought when the sequencing of these conditions, and have opened up searching for copy number variation as a project was launched (pages 6–7). The a host of new therapeutic targets. possible factor in common diseases. Sanger Institute has also shown how Images 1 Buildings housing the Wellcome Trust 3 Dr Mark Walport with Stephen Fry (left) and Sanger Institute. Trust Deputy Chairman Professor Martin 2 Structure of JMJD2A demethylase enzyme, Bobrow (right) at the opening of Wellcome determined by the Structural Genomics Collection. Consortium. 4 Lung cancer cells in culture. DIRECTOR’S STATEMENT 3 HIGHLIGHTS OF THE YEAR much can be gained from comparative This trend towards ‘big science’ is sure genomics – identifying key differences to continue. Progress continues on the between strains and different but related UK Biobank project, which with data on species (pages 10–11). 500 000 people will provide an unrivalled The Cancer Genome Project, a resource for epidemiological research. partnership between the Sanger Institute This year we have promoted more and the Institute of Cancer Research, is imaginative thinking around electronic another ambitious initiative that continues patient records, where the UK’s national to generate important information infrastructure provides a huge (page 7). An early success was its opportunity for health research. The discovery of BRAF as a key gene technical and logistical challenges are involved in malignant melanoma. It now significant but this is an opportunity that must not be let slip away. looks as if BRAF may be exceptional in 4 causing such a high proportion of these The great advances made by large- cancers. An exhaustive trawl of kinase scale initiatives should not cause us to genes in a range of human tumours has lose sight of the high-quality research • Wellcome Trust Case Control revealed great diversity in the mutations being carried out by individual research Consortium finds 30 genes present in cancers. Not all the groups. The work of Professor Adrian associated with common mutations are necessarily contributing Bird and colleagues in Edinburgh and diseases. to cancer growth, and it is a significant researchers at the Behavioural and • Wellcome Trust Sanger Institute challenge distinguishing the ‘drivers’ Clinical Neuroscience Institute in researchers discover further from the ‘passengers’.
Recommended publications
  • Wellcome Trust Annual Report and Financial Statements 2017 Contents

    Wellcome Trust Annual Report and Financial Statements 2017 Contents

    Annual Report and Financial Statements 2017 2 Wellcome Trust Annual Report and Financial Statements 2017 Contents Report from the Chair and the Director 5 Trustee’s Report 8 What we do 8 Review of Charitable Activities 9 Review of Investment Activities 18 Financial Review 29 Structure and Governance 34 Risk Management 37 Remuneration Report 40 Audit Committee Report 43 Independent Auditor’s Report 45 Financial Statements 58 Consolidated Statement of Financial Activities 58 Consolidated Balance Sheet 59 Statement of Financial Activities of the Trust 60 Balance Sheet of the Trust 61 Consolidated Cash Flow Statement 62 Notes to the Financial Statements 63 Reference and Administrative Details 117 3 Wellcome Trust Annual Report and Financial Statements 2017 “ At Wellcome, we believe in the power of ideas to improve health” Jeremy Farrar Director 4 Wellcome Trust Annual Report and Financial Statements 2017 Report from the Chair and the Director “Our core approach is funding people to explore great ideas, at every step of the way from discovery to impact” At Wellcome, we believe in the power of ideas to improve cause of maternal mortality in the world. It also includes health. Funded from our independent investment portfolio, supporting research in the humanities and social sciences, we support thousands of scientists and researchers in more such as a project which this year published ethical guidelines than 70 countries, as well as innovators, educators and artists. for involving pregnant women in Zika vaccine research. Together, we take on big problems, fuel imaginations and spark And resources like the Human Induced Pluripotent Stem Cell debate, working always to achieve better health for everyone.
  • ANNUAL REVIEW 1 October 2005–30 September

    ANNUAL REVIEW 1 October 2005–30 September

    WELLCOME TRUST ANNUAL REVIEW 1 October 2005–30 September 2006 ANNUAL REVIEW 2006 The Wellcome Trust is the largest charity in the UK and the second largest medical research charity in the world. It funds innovative biomedical research, in the UK and internationally, spending around £500 million each year to support the brightest scientists with the best ideas. The Wellcome Trust supports public debate about biomedical research and its impact on health and wellbeing. www.wellcome.ac.uk THE WELLCOME TRUST The Wellcome Trust is the largest charity in the UK and the second largest medical research charity in the world. 123 CONTENTS BOARD OF GOVERNORS 2 Director’s statement William Castell 4 Advancing knowledge Chairman 16 Using knowledge Martin Bobrow Deputy Chairman 24 Engaging society Adrian Bird 30 Developing people Leszek Borysiewicz 36 Facilitating research Patricia Hodgson 40 Developing our organisation Richard Hynes 41 Wellcome Trust 2005/06 Ronald Plasterk 42 Financial summary 2005/06 Alastair Ross Goobey 44 Funding developments 2005/06 Peter Smith 46 Streams funding 2005/06 Jean Thomas 48 Technology Transfer Edward Walker-Arnott 49 Wellcome Trust Genome Campus As at January 2007 50 Public Engagement 51 Library and information resources 52 Advisory committees Images 1 Surface of the gut. 3 Zebrafish. 5 Cells in a developing This Annual Review covers the 2 Young children in 4 A scene from Y fruit fly. Wellcome Trust’s financial year, from Kenya. Touring’s Every Breath. 6 Data management at the Sanger Institute. 1 October 2005 to 30 September 2006. CONTENTS 1 45 6 EXECUTIVE BOARD MAKING A DIFFERENCE Developing people: To foster a Mark Walport The Wellcome Trust’s mission is research community and individual Director to foster and promote research with researchers who can contribute to the advancement and use of knowledge Ted Bianco the aim of improving human and Director of Technology Transfer animal health.
  • The Electron Microscopy Science Technology Platform at the Francis

    The Electron Microscopy Science Technology Platform at the Francis

    The Francis Crick Institute is a The Electron biomedical discovery institute Microscopy dedicated to understanding the fundamental biology underlying Science health and disease. Its work Technology is helping to understand why disease develops and to translate Platform at discoveries into new ways to the Francis prevent, diagnose and treat illnesses such as cancer, heart Crick Institute disease, stroke, infections, and Lucy Collinson neurodegenerative diseases. An independent organisation, its founding partners are the Medical Research Council (MRC), Cancer Research UK, Wellcome, University College London, Imperial College London and King’s College London. The Crick was formed in 2015, with many of the Crick’s scientists joining from two ‘parent’ institutes, the MRC’s National Institute for Medical Research and Cancer Research UK’s London Research Institute, and in 2016 it moved into a brand new state-of- the-art building in central London which brings together 1500 scientists and support staff working collaboratively across disciplines, making it the biggest biomedical research facility under a single roof in Europe. © Nick Guttridge 4 ISSUE 46 JUNE 2017 5 Each microscope room is a six-sided shielded box, • The Phenom-World DelPhi benchtop SEM with walls that contain complex metallic layers has an integrated fluorescence microscope to attenuate DC fields, and an active cancellation for correlative imaging system to attenuate AC fields. Under each • The FEI Twin 120 kV TEM has a cryo stage for microscope is a concrete platform, cast in place, and screening vitrified macromolecular samples supported by air springs that remove environmental prior to imaging on 200 kV and 300 kV TEMs vibration to <1 Hz.
  • Uman Enome News

    Uman Enome News

    uman enome news ISSN:l050-6101 Vol. 3, No.1, May 1991 DOE Holds Contractor-Grantee Workshop Physical Mapping Efforts Going Well; Gels Increasing Sequencing Efficiency he DOE Human Genome Prograll1 held its second Contractor-Grantee Workshop Charles R. Cantor and HGMIS gratefully Tin Santa Fe, New Mexico, on February l7-W. More than 200 program-sponsored acknowledge contribu­ scientists attended the meeting, in addition to invited guests and industry represen­ tions to this article by tatives. DOE-supported human genome research projects are conducted at 7 DOE Elbert W. Branscomb, national laboratories (including its 3 human genome centers), 37 major universities, Anthony V. Carrano, and 32 companies through collaborations and awards. Projects were represented by Leroy E. Hood, oral presentations or posters. Robert K. Moyzis, and Robert J. Robbins. Six platform sessions focused on the more focus is needed on the immediate following: informatics needs of ongoing biology projects. • physical mapping progress, Many parallel efforts under way in cloning, • large DNA fragment cloning, informatics, mapping, and sequencing will • strategies for preparing samples for further improve the technologies required for efficient DNA sequencing, genomics. Program participants feel that this situation is healthy at present and that a few • new methods for a variety of genome efforts, • DNA sequencing instrumentation, and In This fssue .•. • database and computer algorithm needs for existing or projected genome Page Genome News research. 1 DOE Holds Contractor-Grantee Workshop David Galas, Associate Director, Office of 5 LANL, Life Technologies Approve CRADA Health and Environmental Research (OHER), 6 Conncil on Competitiveness Urges Action spoke about the relationship between the 7 Moore Calls Tech Transfer Critical to Fntnre' Human Genome Program and other OHER 8 NIH Discusses eDNA Role with Invited Group programs.
  • A DNA Database in the NHS: Your Freedom up for Sale?

    A DNA Database in the NHS: Your Freedom up for Sale?

    A DNA database in the NHS: Your freedom up for sale? May 2013 In April 2013, the Caldicott Committee, including Government Chief Scientist Sir Mark Walport, proposed new rules for data-sharing which would allow the Government to build a DNA database of the whole population of England in the NHS by stealth.1 The plan is to make NHS medical records and people’s genetic information available to commercial companies and to use public-private partnerships to build a system where all private information about every citizen is also accessible to the police, social workers, security services and Government. The Wellcome Trust, which was involved in the Human Genome Project and was led by Walport for ten years, has produced a plan which involves including a variant file, containing the whole genome of every person minus the reference genome, as an attachment to every medical record in the NHS in England.2 This data would be made available to ‘researchers’ (including commercial companies) for data-mining in the cloud and personalised risk assessments would be returned to individuals. The aim is to transform the NHS in line with proposals developed more than a decade ago by former GlaxoSmithKline Chairman Sir Richard Sykes. This is expected to massively expand the market for medicines, medical tests and other products, such as supplements and cholesterol-lowering margarines, by allowing products to be marketed to individuals based on personal risk assessments, created using statistical analysis of genetic data, medical records and other health information. The proposal to build a DNA database in the NHS was endorsed by the Human Genomics Strategy Group in 20123,4 and the Government (led by Prime Minister David Cameron) has quietly adopted this recommendation without telling members of the public.
  • Structure of Human Aspartyl Aminopeptidase Complexed With

    Structure of Human Aspartyl Aminopeptidase Complexed With

    Chaikuad et al. BMC Structural Biology 2012, 12:14 http://www.biomedcentral.com/1472-6807/12/14 RESEARCH ARTICLE Open Access Structure of human aspartyl aminopeptidase complexed with substrate analogue: insight into catalytic mechanism, substrate specificity and M18 peptidase family Apirat Chaikuad1, Ewa S Pilka1, Antonio De Riso2, Frank von Delft1, Kathryn L Kavanagh1, Catherine Vénien-Bryan2, Udo Oppermann1,3 and Wyatt W Yue1* Abstract Backround: Aspartyl aminopeptidase (DNPEP), with specificity towards an acidic amino acid at the N-terminus, is the only mammalian member among the poorly understood M18 peptidases. DNPEP has implicated roles in protein and peptide metabolism, as well as the renin-angiotensin system in blood pressure regulation. Despite previous enzyme and substrate characterization, structural details of DNPEP regarding ligand recognition and catalytic mechanism remain to be delineated. Results: The crystal structure of human DNPEP complexed with zinc and a substrate analogue aspartate-β- hydroxamate reveals a dodecameric machinery built by domain-swapped dimers, in agreement with electron microscopy data. A structural comparison with bacterial homologues identifies unifying catalytic features among the poorly understood M18 enzymes. The bound ligands in the active site also reveal the coordination mode of the binuclear zinc centre and a substrate specificity pocket for acidic amino acids. Conclusions: The DNPEP structure provides a molecular framework to understand its catalysis that is mediated by active site loop swapping, a mechanism likely adopted in other M18 and M42 metallopeptidases that form dodecameric complexes as a self-compartmentalization strategy. Small differences in the substrate binding pocket such as shape and positive charges, the latter conferred by a basic lysine residue, further provide the key to distinguishing substrate preference.
  • Vol 9 No 1 Spring

    Vol 9 No 1 Spring

    A PUBLICATION OF THE AMERICAN SOCIETY FOR MATRIX BIOLOGY SPRING 2010, VOLUME 9, NO. 1 President’s Letter Expanding the Society’s Value to You and Your Role in the Society Since its inception in 2001, the principal function of the ASMB has been to organize the OFFICERS biennial meeting. The value of this meeting to our members cannot be understated. The ASMB meeting has emerged as the matrix-centric President: meeting in North America, and it provides an William Parks (2010) open venue for students, postdocs, fellows, and junior faculty to present their work and to inter- act with established investigators. Speaking for Vice Pres/President Elect myself, I very much look forward to the ASMB Jean Schwarzbauer (2010) meeting, not only because I get to see many Bill Parks friends, but also to hear a lot of incredibly good science. This year’s meeting will be no excep- Past President: tion and promises to be truly outstanding. I applaud Jean Schwarzbauer and the Renato Iozzo (2010) rest of the Program Committee for putting together an exciting meeting loaded with interesting topics and great speakers (please check out the program here). By organizing the meeting, ASMB provides value to you, the membership, but I Secretary/Treasurer think we–the Society–should always be looking to do more; that is, to provide more Joanne Murphy-Ullrich (2011) bang for your dues buck. For this year’s meeting, we have expanded the Travel Awards that will be given to trainees in recognition of outstanding research, and we recently established merit-based Minority Scholarships that will be awarded to eli- Council Members gible students and postdocs.
  • Jeremy Farrar

    Jeremy Farrar

    FEATURE The BMJ THE BMJ INTERVIEW BMJ: first published as 10.1136/bmj.n459 on 19 February 2021. Downloaded from [email protected] Cite this as: BMJ 2021;372:n459 http://dx.doi.org/10.1136/bmj.n459 Jeremy Farrar: Make vaccine available to other countries as soon as Published: 19 February 2021 our most vulnerable people have received it The SAGE adviser and Wellcome Trust director tells Mun-Keat Looi how the UK government acted too slowly against the pandemic, about the perils of vaccine nationalism, and why he is bullish about controlling covid variants Mun-Keat Looi international features editor “Once the UK has vaccinated our most vulnerable among healthcare workers. We had no human communities and healthcare workers we should make immunity, no diagnostics, no treatment, and no vaccines available to other countries,” insists the vaccines. infectious disease expert Jeremy Farrar. This could Every country should have acted then. Singapore, avert further public health and economic disaster, China, and South Korea did. Yet most of Europe and he says, describing it as “enlightened self-interest, North America waited until the middle of March, and as well as the right ethical thing to do.” that defined the first wave. Countries including the In April 2020, soon after the first UK lockdown began, UK were unwilling to act early, before they felt Farrar predicted that the UK would have one of the comfortable; were unwilling to go deeper than they worst covid-19 death rates in Europe. As a member thought they had to; and were unwilling to keep of the Scientific Advisory Group for Emergencies restrictions in place for as long as was needed.
  • Development of a Genetic Multicolor Cell Labeling Approach for Neural

    Development of a Genetic Multicolor Cell Labeling Approach for Neural

    Development of a genetic multicolor cell labeling approach for neural circuit analysis in Drosophila Dafni Hadjieconomou January 2013 Division of Molecular Neurobiology MRC National Institute for Medical Research The Ridgeway Mill Hill, London NW7 1AA U.K. Department of Cell and Developmental Biology University College London A thesis submitted to the University College London for the degree of Doctor of Philosophy Declaration of authenticity This work has been completed in the laboratory of Iris Salecker, in the Division of Molecular Neurobiology at the MRC National Institute for Medical Research. I, Dafni Hadjieconomou, declare that the work presented in this thesis is the result of my own independent work. Any collaborative work or data provided by others have been indicated at respective chapters. Chapters 3 and 5 include data generated and kindly provided by Shay Rotkopf and Iris Salecker as indicated. 2 Acknowledgements I would like to express my utmost gratitude to my supervisor, Iris Salecker, for her valuable guidance and support throughout the entire course of this PhD. Working with you taught me to work with determination and channel my enthusiasm in a productive manner. Thank you for sharing your passion for science and for introducing me to the colourful world of Drosophilists. Finally, I must particularly express my appreciation for you being very understanding when times were difficult, and for your trust in my successful achieving. Many thanks to my thesis committee, Alex Gould, James Briscoe and Vassilis Pachnis for their quidance during this the course of this PhD. I am greatly thankful to all my colleagues and friends in the lab.
  • 2019-2020 PO No

    2019-2020 PO No

    HOLY CROSS COLLEGE (AUTONOMOUS) Affiliated to Bharathidasan University Nationally Accredited (3rd Cycle) with 'A' Grade by NAAC College with Potential for Excellence. Tiruchirappalli - 620002. PG DEPARTMENT OF BIOCHEMISTRY Programme: M.Sc. BIOCHEMISTRY 2019-2020 PO No. Programme Outcomes Upon completion of the B.Sc. Degree Programme, the graduate will be able to PO-1 To enable to get quality education in the areas of Biochemistry PO-2 Acquire practical skills to gather information, assess, create and execute new ideas to develop entrepreneurial skills. PO-3 Gain Proficiency in basic laboratory techniques and able to apply the scientific method on lab to land PO-4 Inculcate a domestic and international perspective and be competent enough in the area of life sciences. PO-5 Learn to recognize potential laboratory safety and conserve nature and the environment. PSO No. Programme Specific Outcomes Upon completion of these courses the student would PSO-1 Will use current biochemical and molecular techniques and carry out experiments PSO-2 Monitoring the changes in modern life styles leads to modern diseases PSO-3 Develop skills in cultivation of plants. PSO-4 Prepare them to do higher studies in other biological fields like Genetic, Entomology, Biological Oceanography etc PSO-5 Developed critical thinking skills/laboratory techniques to be capable of designing, carrying out ,interpreting scientific experiments 1 HOLY CROSS COLLEGE (AUTONOMOUS) PG DEPARTMENT OF BIOCHEMISTRY (Students admitted from the year 2018 onwards) M.Sc. Biochemistry-Course
  • Science & Policy Meeting Jennifer Lippincott-Schwartz Science in The

    Science & Policy Meeting Jennifer Lippincott-Schwartz Science in The

    SUMMER 2014 ISSUE 27 encounters page 9 Science in the desert EMBO | EMBL Anniversary Science & Policy Meeting pageS 2 – 3 ANNIVERSARY TH page 8 Interview Jennifer E M B O 50 Lippincott-Schwartz H ©NI Membership expansion EMBO News New funding for senior postdoctoral In perspective Georgina Ferry’s enlarges its membership into evolution, researchers. EMBO Advanced Fellowships book tells the story of the growth and ecology and neurosciences on the offer an additional two years of financial expansion of EMBO since 1964. occasion of its 50th anniversary. support to former and current EMBO Fellows. PAGES 4 – 6 PAGE 11 PAGES 16 www.embo.org HIGHLIGHTS FROM THE EMBO|EMBL ANNIVERSARY SCIENCE AND POLICY MEETING transmissible cancer: the Tasmanian devil facial Science meets policy and politics tumour disease and the canine transmissible venereal tumour. After a ceremony to unveil the 2014 marks the 50th anniversary of EMBO, the 45th anniversary of the ScienceTree (see box), an oak tree planted in soil European Molecular Biology Conference (EMBC), the organization of obtained from countries throughout the European member states who fund EMBO, and the 40th anniversary of the European Union to symbolize the importance of European integration, representatives from the govern- Molecular Biology Laboratory (EMBL). EMBO, EMBC, and EMBL recently ments of France, Luxembourg, Malta, Spain combined their efforts to put together a joint event at the EMBL Advanced and Switzerland took part in a panel discussion Training Centre in Heidelberg, Germany, on 2 and 3 July 2014. The moderated by Marja Makarow, Vice President for Research of the Academy of Finland.
  • Financing Vaccines for Global Health Security

    Financing Vaccines for Global Health Security

    NBER WORKING PAPER SERIES FINANCING VACCINES FOR GLOBAL HEALTH SECURITY Jonathan T. Vu Benjamin K. Kaplan Shomesh Chaudhuri Monique K. Mansoura Andrew W. Lo Working Paper 27212 http://www.nber.org/papers/w27212 NATIONAL BUREAU OF ECONOMIC RESEARCH 1050 Massachusetts Avenue Cambridge, MA 02138 May 2020 We thank Ellen Carlin, Doug Criscitello, Margaret Crotty, Narges Dorratoltaj, Per Etholm, Jeremy Farrar, Nimah Farzan, Mark Feinberg, Jose-Maria Fernandez, John Grabenstein, Peter Hale, Richard Hatchett, Peter Hotez, Daniel Kaniewski, Adel Mahmoud, Mike Osterholm, May 2020 Farrar, Nimah Kevin Outterson, Chi Heem Wong, CEPI leadership, and two reviewers and the editor for helpful comments and discussion, and Jayna Cummings for editorial assistance. Research support from the MIT Laboratory for Financial Engineering and the Warren Alpert Medical School of Brown University is gratefully acknowledged. The views and opinions expressed in this article are those of the authors only, and do not necessarily represent the views and opinions of any institution or agency, any of their affiliates or employees, any of the individuals acknowledged above, or the National Bureau of Economic Research. Funding support from the MIT Laboratory for Financial Engineering is gratefully acknowledged, but no direct funding was received for this study and no funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of this manuscript. The authors were personally salaried by their institutions during the period of writing (though no specific salary was set aside or given for the writing of this manuscript). At least one co-author has disclosed a financial relationship of potential relevance for this research.